This article will provide helpful pointers from Paul Terrill, Director of Strategic Consulting at Cytel to ensure smooth communication between statistical and clinical stakeholders.
Insights into the impact that the shutdown will have on the FDA and on the review of investigational products, including those reviews which were already in process at the time of the shutdown.
IRT professionals can bring together supply chain and clinical team staff for discussions on actual trial needs. Learn how including IRT professionals earlier in the planning phase of clinical trials may result in a better understanding of supply chain needs. This can increase the efficiency of inventory management and lead to unforeseen cost savings over the course of the trial.
Take these steps to create a trusted partnership with your CRO and achieving a much more accurate and financially workable CRO agreement.
Adaptive design strategies have been especially useful for rare disease research in general and rare oncology in particular. Read more to see how the savvy application of adaptive trial design compares to conventional study designs.
For patients battling rare cancers, especiall those lacking standard treatments, they don’t have the time to wait for more concrete measures. In these cases, choosing the appropriate endpoint for a trial is crucial. Read on for a rundown of the five major types of clinical endpoints in rare oncology and the best way to use them.
Transparency means different things to different segments of the healthcare industry and to consumers themselves. In this blog, a former R.N. and clinical trial participant shares her insights on why clinical trial transparency is so important.
As sponsors increasingly outsource their clinical trial operations to CROs in search of greater cost efficiency there is a higher premium on eClinical technology and other resources that empower CROs to better navigate that competition.
Here are five things you should know about iRECIST as the standard shapes up as an important tool in assessing solid tumors.
Key considerations for developing early-phase trials that can more accurately define the recommended dose and identify adverse events for emerging therapies.
|
|
|
|
|
|
|
|
|